VIB Feb 1 2026 An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how antibody medicines are tested and brought to patients. The work, published in Science Immunology , highlights problems during conventional antibody drug testing and introduces a next-generation mouse model that makes it possible to predict the effects of antibody drugs in humans more accurately.  Antibody-based medicines are widely used to treat cancer,